Squamous cell carcinoma of head and neck (SCCHN) is one of the most common malignancies worldwide, and nucleotide excision repair (NER) is involved in SCCHN susceptibility. In this analysis of 349 newly diagnosed SCCHN patients and 295 cancer-free controls, we investigated whether expression levels of eight core NER proteins were associated with risk of SCCHN. We quantified NER protein expression levels in cultured peripheral lymphocytes using a reverse-phase protein microarray. Compared with the controls, SCCHN patients had statistically significantly lower expression levels of ERCC3 and XPA (P = 0.001 and 0.001, respectively). After dividing the subjects by controls' median values of expression levels, we found a dose-dependent association between an increased risk of SCCHN and low expression levels of ERCC3 (adjusted OR, 1.75, and 95% CI: 1.26-2.42; P trend = 0.008) and XPA (adjusted OR, 1.88; 95% CI, 1.35-2.60; P trend = 0.001). We also identified a significant multiplicative interaction between smoking status and ERCC3 expression levels (P = 0.014). Finally, after integrating demographic and clinical variables, we found that the addition of ERCC3 and XPA expression levels to the model significantly improved the sensitivity of the expanded model on SCCHN risk. In Abbreviation: BPDE, benzo (a) pyrene diol epoxide; CI, confidence interval; DRC, DNA repair capacity; HCR, host-cell reactivation; NER, nucleotide excision repair; OR, odds ratio; ROC, receiver operating characteristic; RPPA, reverse-phase protein lysate microarray; SCCHN, squamous cell carcinoma of head and neck; XP, xeroderma pigmentosum.
conclusion, reduced protein expression levels of ERCC3 and XPA were associated with an increased risk of SCCHN. However, these results need to be confirmed in additional large studies.
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biomarker, DNA repair, head and neck cancer, NER pathway, protein expression States. [3] [4] [5] Several key factors may contribute to SCCHN, such as cigarette smoking and alcohol use for non-HPV SCCHN as well as prior HPV infection for HPV-positive oropharyngeal cancer, but only a small fraction of the population exposed develop SCCHN in their lifetime. 6, 7 Although the underling mechanisms are still not fully studied, the heterogeneity in DNA repair mechanism may be responsible for the susceptibility to SCCHN.
Benzo(a)pyrene diol epoxide (BPDE) is a classic tobacco carcino-
gen that can cause irreversible DNA damage by forming DNA adducts. [8] [9] [10] DNA repair is a response to protect against DNA damage through several pathways, of which the nucleotide excision repair (NER) pathway is a major one. [11] [12] [13] Eight core proteins (DDB1, ERCC1-5, XPA, and XPC) are involved in the NER process that includes damage recognition (DDB1, XPA, and XPC), dual incision and oligonucleotide fragment removal (ERCC2/XPD and ERCC3/XPB), gap-filling synthesis and restore DNA duplex (ERCC1, ERCC4/XPF, and ERCC5/XPG), and ligation. [14] [15] [16] Variation in these proteins' functions may lead to an aberrant NER process and subsequently increase the susceptibility to cancer. 17 Humans with defective NER proteins may have NERassociated diseases, such as xeroderma pigmentosum (XP), Cockayne's syndrome, and trichothiodystrophy. 18, 19 In addition, double strand break (DSB) repair may also play an important role in HPV-related oropharyngeal cancer, and our team recently reported an association between the reduced DSB repair capacity and increased risk of SCCHN as well. 20, 21 In early phenotype studies, we first reported that reduced DNA repair capacity as measured by a host cell reactivation (HCR) assay was associated with an increased risk of SCCHN, 22 and later we validated these results in a larger study. 23 In order to determine the molecular mechanism underlying the NER pathway, we conducted two studies measuring the transcript levels of the core NER genes and found an increased risk of SCCHN was associated with reduced mRNA expression levels in lymphoblastoid cells. 24, 25 However, the transcript levels may not exactly represent the translational levels of NER proteins, because the latter more directly participate in the repair process. Thereafter, we had developed a high-throughput reversephase protein lysate microarray (RPPA) assay to measure the NER proteins expression levels in a pilot study of 120 subjects and reported that an increased risk of SCCHN was associated with reduced expression levels of ERCC2, ERCC4, XPA, and XPC. 26 Nevertheless, the previous association study of NER proteins had a relatively small size, and due to the lack of appropriate antibodies in the past, we were not able to measure the expression levels of DDB1 and ERCC3, which may also play a crucial role in NER. Consequently, a larger study was warranted to validate the previous study of associations between NER proteins and risk of SCCHN. Thus, we conducted a larger case-control study with 644 subjects to evaluate associations between expression levels of eight core NER proteins and risk of SCCHN. As there were no significant differences in the transcript levels of eight NER genes by HPV status as we showed before, 25 we tested expression levels of NER proteins in all SCCHN subjects.
| MATERIALS AND METHODS

| Study subjects
We recruited SCCHN cases and cancer-free controls from The and sex, and have no history of prior cancers. To avoid genetic heterogeneity due to ethnic differences, the subjects included in currently study were all non-Hispanic whites. A written informed consent was obtained from eligible cases and controls. As the method described in most of epidemiology studies, 27,28 subjects who smoked more than 100 cigarettes during their lifetime were defined as ever smokers, of which those who had quit smoking at least 1 year were defined as former smokers and remaining were considered current smokers; others were considered never smokers. Subjects who drank alcoholic beverages at least weekly for 1 year were considered as ever drinkers, of which those who had quit drinking more than one year were considered as former and the remaining were defined current drinkers; others were defined never drinkers. The study protocol was reviewed and approved by M.D. Anderson Institutional Review Board.
| Sample procurement, cell culture, and protein preparation
The current methods have been described previously. 26 Briefly, each subject donated a 30-mL blood sample drawn into a heparinized tube before receiving treatment for cases and when consent was obtained for controls. We isolated T-lymphocytes from whole peripheral blood by Ficoll gradient centrifugation, and cryopreserved in a −80°C freezer within 24 h after the blood was drawn. To ensure a robust cellular viability (>80%), which was confirmed by the exclusion assay using were labeled with biotin, and added to the slides, which were then incubated at room temperature for 30 min.
Signals were amplified using a Dako Cytomation-Catalyzed system according to the manufacturer's protocol as previously described. 29 We then incubated the slides with a secondary concentration of each protein on the X-axis using the non-parametric, monotone increasing B-spline model. 30 Protein concentrations were determined from the supercurve for each lysate by the curve-fitting.
The relative concentrations of each protein were normalized for protein loading and transformed to linear values. 29, 31 The RPPA_CF is the correction factor in RPPA. Samples were considered as an outlier, if the correction factor was above 2.5 or below 0.25.
| Statistical analysis
The distributions of selected demographic variables, tobacco smoking, and alcoholic beverage consumption were evaluated between patients and controls by the χ 2 test. The differences in the relative expression levels of NER proteins as continuous variables were compared by
Wilcoxon rank-sum test or ANOVA among groups. In addition, the correlations between the expression levels of the eight NER proteins were analyzed by the Spearman's correlation coefficient. In addition,
we performed a stepwise logistic regression analysis to explore the best model to predict SCCHN risk.
The median and quartiles of protein expression values in the controls were used as the cutoff values for calculating crude odds ratio (OR) and their 95% confidence intervals (CI). The associations between NER protein expression levels and SCCHN risk were estimated by computing ORs and CIs from multivariate logistic regression models with adjustment for age (in years), sex (male vs female), smoking status (never, former, or current), and alcohol consumption (never, former, or current).
Further stratification analyses were used to evaluate effect modification of related NER proteins and selected variables. A multiplicative interaction was defined as when OR 11 > OR 10 × OR 01 , in which OR 11 was the OR when both factors were present, OR 01 was the OR when only factor 1 was present, and OR 10 was the OR when only factor 2 was present. 23 We analyzed the interactions by looking for a multiplicative scale using standard unconditional logistic regression models.
To evaluate the effects of protein expression levels on SCCHN risk prediction in the multivariate model, two risk models were constructed to examine the area under the receiver operating characteristic (ROC) curve (AUC): the baseline model including only epidemiologic variables (eg, age, sex, smoking, and drinking status), and the protein model including the protein expression (continuous variable) in addition to these epidemiologic variables. Furthermore, the AUC was calculated upon stratification by smoking status (never, former, and current). All tests were two-sided, and P < 0.05 was considered significant. All statistical analyses were performed using SAS software (version 9.4; SAS Institute, Inc., Cary, NC).
3 | RESULTS
| Characteristics of the subject population
The summary of the distributions of demographic variables and tumor characteristics between cases and controls was presented in Table 1 .
There were no significant differences in the distributions of age and sex between SCCHN patients and cancer-free controls. Moreover, no significant differences were observed in the distributions of age, sex, smoking, and drinking status between the included and excluded subjects (Supplementary Table S1 ), suggesting that no selection bias was introduced in the current study. 
| Differences in relative expression levels of NER proteins between cases and controls
We evaluated the differences in NER protein expression levels between cases and controls by Wilcoxon rank-sum test (Table 2) .
Among all eight NER proteins, only ERCC3 and XPA expression levels were statistically significantly lower in cases than in controls (P = 0.001
and P = 0.001, respectively; Figure 1A ). Because the expression levels of the eight NER proteins were measured at the same time, they were likely to be correlated with each other. As shown in Table 3 , expression levels of ERCC3 were statistically significantly correlated with all other six NER proteins, except for XPA; while expression levels of XPA were statistically significantly correlated with ERCC1, ERCC2, ERCC4, and ERCC5. Subsequently, when we included the expression levels of ERCC3 and XPA in the stepwise logistic regression analysis after adjustment for age, sex, smoking and alcohol use, both ERCC3 and XPA remained in the final model (P = 0.007 and P = 0.002, respectively),
suggesting that the effects of these two NER proteins were independent.
| Stratification analyses of expression levels of ERCC3 and XPA
Stratification analyses of ERCC3 and XPA expression levels showed that cases in subgroups of the age >56, male, never and former smokers, and current drinkers exhibited significantly lower mean expression levels of ERCC3 than did controls (P = 0.001, P = 0.002, P = 0.010, P = 0.002, and P = 0.007, respectively, Table 4 ). Likewise, cases in subgroups of the age ≤56 and age >56, male and female, current smokers, and current drinkers exhibited significantly lower mean expression of XPA than did controls (P = 0.023, P = 0.018, P = 0.008, P = 0.017, P = 0.032, and P = 0.002, respectively). In both cases and controls, the age and sex differences in the expression levels of ERCC3 and XPA were all statistically insignificant (P = 0.065, P = 0.997, P = 0.774, P = 0.967, P = 0.861, P = 0.518, P = 0.663, and P = 0.245, respectively). In controls, current smokers had lower expression levels of ERCC3 than that of former and never smokers, | 787 and the differences of ERCC3 expression levels were statistically significant (P = 0.022), but such a difference was not observed in cases (P = 0.154, Table 4 ). The differences in the expression levels of ERCC3
and XPA were not statistically significant by sex in both cases and controls, nor by tumor sites (Supplementary Table S2 ). Furthermore, we conducted a case-case analysis of 96 SCCHN cases and 58
oropharyngeal cases who had both the available HPV status and protein expression data, and we found that expression levels of ERCC3
and XPA were not differed by the HPV status (Supplementary Table S3 ).
| Associations between NER protein expression levels and risk of SCCHN
To estimate SCCHN risk, the relative NER protein expression levels were dichotomized by the median values of the controls (Table 5 and Supplementary with adjustment for all covariates, there was also a dose-response relationship between the reduced protein expression levels and the increased SCCHN risk for both ERCC3 (P trend = 0.008) and XPA (P trend = 0.001, Table 5 ).
| Interactions between ERCC3 or XPA expression levels and selected variables
We further assessed possible interactions on a multiplicative scale between expression levels of ERCC3 or XPA and selected variables | 789 smokers were greater than those of never smokers ( Figure 1B) .
However, the associations between the low expression levels of ERCC3 and risk of SCCHN in current smokers were not statistically significant.
We further assessed the prediction performance of models integrating demographic variables and protein expression levels on SCCHN risk using the ROC curves that measure the effect of ERCC3
and XPA expression levels in two dimensions. The AUC was significantly improved in the model that included the combined effect of ERCC3 and XPA expression levels, compared with the model that did not (Figure 2A , P = 0.023). Furthermore, the AUC was significantly improved in never and former smokers that included the combined effect of expression levels, but insignificantly improved in current smokers, compared with the model that did not ( Figure 2B -D, P = 0.039, P = 0.015, and P = 0.158, respectively).
| DISCUSSION
In the current study, we further confirmed the results in the previous pilot study that reduced NER protein expression levels as measured by the RPPA assay were associated with an increased risk of SCCHN.
Specifically, our results demonstrated that the reduced relative protein expression levels of XPA and ERCC3 were associated with an increased risk of SCCHN. Furthermore, we found that smoking status had a significant multiplicative interaction with ERCC3 expression levels on SCCHN risk. The AUC model suggested that the combined effect of ERCC3 and XPA further improved the efficacy of risk prediction.
In previous studies, we developed the HCR assay to measure the association between the SCCHN susceptibility and impaired DRC. The results suggested that suboptimal DRC was associated with an increased SCCHN risk, and we further confirmed that DRC was an independent biomarker for SCCHN susceptibility rather than a tumor marker. 22, 23 Later, another study indicated a correlation between suboptimal DRC phenotype and NER mRNA expression levels in the lymphocytes. 32 Subsequently, we measured the NER mRNA expression levels of SCCHN cases and healthy controls in their peripheral lymphocytes by using a PCR assay. The results suggested that the relative mRNA expression levels of DDB1 and ERCC3 were significantly lower in cases than in controls, and the risk of SCCHN associated with low expression levels of the two genes was about twofold. 24, 25 As the mRNA is eventually translated into a protein, one might assume that there might be a correlation between the level of mRNA and that of the protein. However, the association between NER mRNA expression and SCCHN risk may be spurious, as the transcript levels and translational levels may not be significantly correlated. 33 It was reported that transcription and translation are far from having a linear and simple relationship. The possible reason behind this is that different mechanisms involving cis-acting and trans-acting mechanisms generate a repertoire of systems that enhance or repress the synthesis of proteins from a certain copy number of mRNA molecules. 34 To address this underlying discrepancy, we used the RPPA assay to measure the NER protein expression levels in a preliminary study and found that there was an association between an increased risk of SCCHN and reduced expression levels of ERCC2, ERCC4, XPA, and XPC, 26 when appropriate antibodies for DDB1 and ERCC3 were not available. In the current larger study with more available antibodies for essential proteins, we confirmed that reduced XPA expression was associated with an increased SCCHN risk but found a new association with ERCC3 expression levels, which is also in accordance with our previous transcriptional studies. 24, 25 Collectively, these results suggested that altered protein expression levels, which have a more direct effect on the NER capacity than that of transcript levels, may contribute to the risk of SCCHN.
As the etiologic mechanism for HPV-positive oropharyngeal cancer is different from other non-HPV SCCHN, 35, 36 we compared the expression levels of ERCC3 and XPA between HPV-positive cases and HPV-negative cases, the results confirmed that the expression levels of ERCC3 and XPA were not correlated with the HPV status.
Moreover, we also found that there are no differences in these two proteins between different tumor sites, suggesting that expression levels of ERCC3 and XPA may be a general biomarker for all SCCHN tumors.
Our previous studies found that significantly lower mRNA expression levels of NER genes in female controls than in male controls, and the reduced DDB1 mRNA expression levels may play a more important role in the risk of SCCHN in males than in females. 25 However, we did not observe any significant differences in the protein expression levels of ERCC3 and XPA between male and female subjects, nor did find any interaction with sex. Interestingly, we have observed a modification effect of smoking status on ERCC3, which is in accordance with our DRC study, 23 indicating that an association between the reduced expression levels of ERCC3 and increased risk of SCCHN may differ by smoking status. Subsequently, we stratified the ORs by smoking status and found that the adjusted ORs for ERCC3 in former smokers were greater than that in never smokers, indicating that former smokers have a higher risk of developing SCCHN with a lower ERCC3 expression. Even though the results in the protein study is different from that of the mRNA study, protein levels are likely more directly involved in the NER repair process.
The ERCC3 was a subunit of the transcription factor IIH functioning as a DNA-dependent ATPase-helicase, which is actively FIGURE 2 Overall and stratified ROC curves by smoking status calculated in multivariate logistic models. A, The AUC was significantly improved in the model that included the combined effect of ERCC3 and XPA expression levels, compared with the model that did not (P = 0.023); (B) The AUC was significantly improved in never smokers that included the combined effect of ERCC3 and XPA expression levels (P = 0.039); (C) The AUC was significantly improved in former smokers that included the combined effect of ERCC3 and XPA expression levels (P = 0.015); (D) The AUC was insignificantly improved in current smokers (P = 0.158)
involved in NER. 37, 38 The finding of reduced expression levels of ERCC3 associated with an increased risk of SCCHN in the present study is consistent with that of our previous study of NER transcript levels. These suggest that levels of both ERCC3 transcript and protein are predictors of SCCHN risk.
The XPA is a zinc-finger DNA-binding protein that participates in NER to detect DNA damage. 39 We further confirmed the results of our previous translational analysis that reduced XPA expression levels were associated with an increased risk of SCCHN. These suggest that levels of XPA protein expression but not its transcripts may be a biomarker for SCCHN risk. Interestingly, of 461 SNPs reported to date for XPA, a common 23A > G SNP (rs1800975) in the 5′-UTR has been widely studied. [40] [41] [42] In a meta-analysis study, a significant association of XPA A23G variant with head and neck cancer risk was observed, providing further genotype evidence for the role of XPA in SCCHN risk. 43 Recently more studies showed the positive performance of phenotypic and genotypic markers in risk prediction models by calculating the AUC under the ROC curve. 44, 45 Previously, we assessed the performance of two biomarkers of DRC in the AUC model and
found that the addition of DRC significantly improved the prediction of lung cancer risk. 46 Later, we reported the improvement on prediction of SCCHN risk by adding DRC phenotype, and the results showed the improvement was more evident in never smokers than in ever smokers. 23 Furthermore, we found an improvement in AUC by adding the combined effect of NER mRNA expression and its interaction effects, compared with the baseline model. 25 In the current study, we
found that the AUC model was significantly improved by including the combined effect of ERCC3 and XPA expression, compared with the model that did not, especially in former smokers. Collectively, these results suggested that reduced expression levels of NER proteins may play an important role in SCCHN risk, especially in former smokers.
To date, we have developed several methods to measure biomarkers at mRNA, protein or DRC levels that may predict the risk of tobacco-induced SCCHN. [23] [24] [25] [26] The RPPA assay is a rapid, costeffective and most importantly an efficient method to measure the DRC.
First, compared with the PCR assay, the RPPA assay is more sensitive and reliable, as the expression levels measured by PCR may fluctuate in different cell stage. Second, compared with Western blot assay, the RPPA assay only requires a much small amount of protein lysate samples, and many samples can also be tested simultaneously under the same condition. Third, compared with the HCR assay, the PRRA assay demands a relatively fewer viable lymphocytes for protein extraction, and the peripheral blood lymphocytes are easier to obtain from population-based studies. Therefore, the RPPA assay using peripheral blood lymphocytes is an optimal assay for future epidemiologic studies.
Although the present study is an extension of our previous work for NER proteins with more antibodies and larger sample size, there are still several limitations needed to be resolved. Like our previous hospital-based studies, the control group may not be representative of the general population, and future studies may need a much larger sample size, and recruit the controls from the community-based population. Future mechanistic studies are also needed for the role of NER proteins in the etiology of SCCHN.
